Appetite control system -
Peripherally, CCK A receptors are found in the pancreas, on vagal afferent and enteric neurons. CCK B receptors are also distributed widely in the brain, are present in the afferent vagus nerve, and are found within the stomach Moran et al.
The CCK A receptor subtype is thought to mediate the effect of the endogenous agonist on appetite Asin et al. Suppression of food intake is only seen in response to the sulphated form of CCK which binds with high affinity to CCK A receptors Gibbs et al. Further-more, administration of a CCK A receptor antagonist increases calorie intake and reduces satiety Hewson et al.
The vagal nerve projects to the NTS, which in turn relays information to the hypothalamus Schwartz et al. Peripheral CCK may act both on the vagal nerve and directly on the CNS by crossing the blood—brain barrier Reidelberger et al.
Evidence from the CCK A receptor-knockout OLETF rat suggests that CCK may act on the DMH to suppress NPY levels Bi et al. This is supported by data which demonstrate that administration of CCK to the DMH inhibits food intake significantly Blevins et al.
CCK may also act as a longer-term indicator of nutritional status: the CCK A receptor-knockout OLETF rat but not the CCK A receptor-knockout mouse is hyper-phagic and obese Moran et al.
Chronic administration of both CCK antibodies and CCK A antagonists also results in weight gain in rodent models, although not with a significant increase in food intake McLaughlin et al. The long-term effect of CCK on body weight may partially result from an interaction with signals of adiposity such as leptin, which enhance the satiating effect of CCK Matson et al.
See Figure 4. The brain integrates peripheral signals of nutrition in order to maintain a stable body weight. However, in some individuals, genetic and environmental factors interact to result in obesity.
Understanding of the complex system which regulates energy homeostasis is progressing rapidly, enabling new obesity therapies to emerge. Available pharmacological agents, such as sibutramine and orlistat, have limited efficacy and are restricted to 1 or 2 years of therapy respectively see review by Finer Currently, the only obesity treatment in clinical use that has shown significant long-term weight loss is gastrointestinal bypass surgery Frandsen et al.
However, because of its complications, this procedure is restricted to patients with morbid obesity. This suggests that therapies based on these hormones may be effective in the long term, without the need for surgical intervention. As mechanisms of disordered energy homeostasis are clarified, treatments based on peripheral hormones or central neuropeptide signals could be tailored to the individual; just as leptin deficiency is treated successfully with leptin replacement.
Therapeutic strategies may thus significantly impact on the enormous morbidity and mortality associated with obesity, as even modest weight loss can reduce the risk of diabetes, cancer and cardiovascular disease.
The ARC and the control of appetite. α-MSH, α-melanocyte-stimulating hormone; GHS-R, growth hormone secretagogue receptor.
Citation: Journal of Endocrinology , 2; Schematic of the hypothalamic nuclei coronal section. BDNF, brain-derived neurotrophic factor; CRH, corticotrophin-releasing hormone; MCH, melanin-concentrating hormone; ME; median eminence; PFA, perifornical area; TRH, thyrotropin-releasing hormone.
The central control of appetite. AP, area postrema; ME; median eminence; NAc, nucleus accumbens; PFA, perifornical area. K W is supported by the Wellcome Trust, B M is supported by the Wellcome Trust and S S is supported by the Medical Research Council. Lack of evidence to support a role for the melanocortinreceptor.
Brain Research — Abbott CR , Rossi M, Wren AM, Murphy KG, Kennedy AR, Stanley SA, Zollner AN, Morgan DG, Morgan I, Ghatei MA et al.
Endocrinology — Gut 17 — Digestion 21 — Gastroenterology 89 — Nature — Nature Medicine 8 — Science — Digestion 30 — Obesity Surgery 12 — Journal of Biological Chemistry — Journal of Clinical Endocrinology and Metabolism 87 — Arita Y , Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K et al.
Biochemical and Biophysical Research Communications 79 — Ariyasu H , Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S et al. Journal of Clinical Endocrinology and Metabolism 86 — Journal of Clinical Endocrinology and Metabolism 88 — Peptides 20 — Gastroenterology — American Journal of Physiology —Regulatory, Integrative and Comparative Physiology R60 —R Journal of Clinical Investigation 46 — Neuron 42 — Banks WA The source of cerebral insulin.
European Journal of Pharmacology 5 — Peptides 17 — Brain Research 79 — New England Journal of Medicine — A mechanism for regulated insulin delivery to the brain. Journal of Clinical Investigation 92 — American Journal of Physiology — Regulatory, Integrative and Comparative Physiology R —R Journal of Neuroscience 20 — Journal of Neuroscience 22 — Nature Medicine 7 — Neuroscience and Biobehavioral Reviews 20 — Peptides 14 — Berridge KC Modulation of taste affect by hunger, caloric satiety, and sensory-specific satiety in the rat.
Appetite 16 — Bristish Medical Journal 2 — Black SC Cannabinoid receptor antagonists and obesity. Current Opinion in Investigational Drugs 5 — Brain Research 1 — European Journal of Cell Biology 82 53 — Borowsky B , Durkin MM, Ogozalek K, Marzabadi MR , DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I et al.
Comparative Journal of Neurology — Neuroendocrinology 66 — PNAS 95 — Butler AA Studies defining the role of the melanocortin-3 receptor in the development of obesity and insulin resistance. American Endocrine Society, New Orleans , Abstract OR Diabetes 48 — Journal of Clinical Endocrinology and Metabolism 89 — Journal of Neuroscience 23 — Biochemical and Biophysical Research Communications — Challis BG , Coll AP, Yeo GS, Pinnock SB, Dickson SL, Thresher RR, Dixon J, Zahn D, Rochford JJ, White A et al.
PNAS — Journal of Clinical Investigation — Nature Genetics 12 — Chemelli RM , Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y et al. Cell 98 — Cell 84 — Chen HY , Trumbauer ME, Chen AS, Weingarth DT, Adams JR, Frazier EG, Shen Z, Marsh DJ, Feighner SD, Guan XM et al.
Journal of Neuroscience 24 — Brain Research 89 — Experientia 35 — Genomics 45 — Regulatory Peptides 17 31 — Clement K , Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM et al.
Coleman DL Obesity genes: beneficial effects in heterozygous mice. International Journal of Obesity and Related Metabolic Disorders 25 Suppl 5 S63 —S Conlon JM The origin and evolution of peptide YY PYY and pancreatic polypeptide PP. Peptides 23 — Brain Research Molecular Brain Research 79 — Considine RV , Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL et al.
Neuroscience Letters 70 17 — Peptides 22 — Cota D , Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S et al.
Journal of Clinical Investigations — Journal of Chemical Neuroanatomy 12 — Neuron 24 — Cowley MA , Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML et al. Neuron 37 — Peptides 15 — Diabetes 50 — American Journal of Physiology — Endocrinology and Metabolism E —E Date Y , Nakazato M, Hashiguchi S, Dezaki K, Mondal MS, Hosoda H, Kojima M, Kangawa K, Arima T, Matsuo H et al.
Diabetes 51 — De Lecea L , Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS et al. Journal of Neuroendocrinology 14 — Physiology and Behavior 51 — Journal of Neuroscience 18 — Eberlein GA , Eysselein VE, Schaeffer M, Layer P, Grandt D, Goebell H, Niebel W, Davis M, Lee TD, Shively JE et al.
Peptides 10 — Journal of Endocrinology R7 —R Neuron 21 — Neuron 23 — Recent Progress in Hormone Research 59 — Nature Neuroscience 1 — Journal of Clinical Endocrinology and Metabolism 87 Nature 34 — PNAS 94 — Finer N Pharmacotherapy of obesity.
Best Practice and Research. Clinical Endocrinology and Metabolism 16 — International Journal of Obesity and Related Metabolic Disorders 25 — Physiology and Behavior 66 — European Journal of Surgery — Impact of nutrition and obesity.
Journal of Clinical Investigation 96 — PNAS 98 — Pflugers Archiv — Biological Psychiatry 41 — Neuroscience Letters 49 — Journal of Clinical Endocrinology and Metabolism 57 — Journal of Comparative Physiology and Psychology 84 — Hormone and Metabolic Research 20 — Journal of Neuroscience Research 67 — Biopolymers 22 — Peptides 19 — Frontiers in Neuroendocrinology 23 2 — Brain Research Molecular Brain Research 59 — Hagan JJ , Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P et al.
PNAS 96 — Brain Research 20 — American Journal of Physiology —Regulatory, Integrative and Comparative Physiology R47 —R American Journal of Physiology —Regulatory, Integrative and Comparative Physiology R —R Journal of Physiology 51 — Clinical Endocrinology Oxford 56 — Acta Physiologica Scandinavica — Heisler LK , Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H et al.
Digestion 56 — British Journal of Pharmacology 93 79 — Journal of the American Medical Association — Scandiavian Journal of Gastroenterology 36 — Holst JJ Glucagon-like peptide 1 GLP-1 : an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends in Endocrinology and Metabolism 10 — Holst JJ Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Expert Opinion on Emerging Drugs 9 — Scandiavian Journal of Gastroenterology 14 — International Journal of Obesity 7 — Journal of Neuroscience 19 — Hotta K , Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K et al.
Arteriosclerosis, Thrombosis, and Vascular Biology 20 — Nature Medicine 10 — Brain Research 9 — Huszar D , Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD et al. Cell 88 — Appetite 7 — Inui A Neuropeptide Y feeding receptors: are multiple subtypes involved?
Trends in Pharmacological Sciences 20 43 — PNAS 88 — Endocrine Reviews 20 68 — Regulatory Peptides 92 37 — Journal of Molecular Neuroscience 18 7 — Brain Research 21 — Kim MS , Rossi M, Abusnana S, Sunter D, Morgan DG, Small CJ, Edwards CM, Heath MM, Stanley SA, Seal LJ et al.
Diabetes 49 — Journal of Neurochemistry 73 — European Journal of Pharmacology R1 —R3. American Journal of Clinical Nutrition 34 — Comparative Journal of Neurology 1 — Lancet 2 — Nature 72 — Nature Genetics 19 — Kubota N , Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H et al.
Kuo DY Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats.
Journal of Biomedical Science 9 — Brain Research 59 — Synapse 29 — Larhammar D Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regulatory Peptides 65 — Evidence for the occurrence of three distinct cell types storing COOH-terminal gastrin immunoreactivity.
Histochemistry 58 23 — Cell Tissue Research — Diabetes 29 — Journal of Clinical Endocrinology and Metabolism 74 — Molecular forms, responses to feeding, and relationship to gallbladder contraction.
Journal of Clinical Investigation 75 — Regulatory Peptides — Lu D , Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO et al. Lubrano-Berthelier C , Cavazos M, Dubern B, Shapiro A, Stunff CL, Zhang S, Picart F, Govaerts C, Froguel P, Bougneres P et al.
Annals of the New York Academy of Sciences 49 — Human Molecular Genetics 12 — Diabetes 51 Suppl 3 S —S Maeda N , Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y et al.
Maffei M , Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S et al. Nature Medicine 1 — BMC Neuroscience 3 Journal of Neuroendocrinology 12 — Experientia 33 — American Journal of Medical Genetics A — Nature Medicine 4 — Brain Research 66 — Marsh DJ , Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, Guan XM, Jiang MM, Feng Y, Camacho RE et al.
PNAS 99 — Nature Medicine 3 — Physiology and Behavior 26 — Physiology and Behavior 34 — Journal of Neuroendocrinology 8 — Endocrinology 29 — Metabolism 35 — International Journal of Obesity and Related Metabolic Disorders 28 — Obesity Surgery 11 — American Journal of Physiology Gastrointestinal and Liver Physiology G —G Peptides 6 — Montague CT , Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA et al.
Critical Reviews in Neurobiology 9 1 — Brain Research 95 — Neuroscience Letters — Morris BJ Neuronal localisation of neuropeptide Y gene expression in rat brain. Molecular Endocrinology 8 — Journal of Endocrinology — Naslund E Prandial subcutaneous injections of GLP-1 cause weight loss in obese human subjects.
Horm Metab Res 32 : 62 — Mollet A , Meier S , Grabler V , Gilg S , Scharrer E , Lutz TA Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin. Peptides 24 : 91 — Whitehouse F , Kruger DF , Fineman M , Shen L , Ruggles JA , Maggs DG , Weyer C , Kolterman OG A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Diabetes Care 25 : — Hollander PA , Levy P , Fineman MS , Maggs DG , Shen LZ , Strobel SA , Weyer C , Kolterman OG Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Diabetes Care 26 : — Wiedmer P , Nogueiras R , Broglio F , D'Alessio D , Tschop MH Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 3 : — Cummings DE , Purnell JQ , Frayo RS , Schmidova K , Wisse BE , Weigle DS A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.
Diabetes 50 : — Asakawa A , Inui A , Kaga T , Yuzuriha H , Nagata T , Ueno N , Makino S , Fujimiya M , Niijima A , Fujino MA , Kasuga M Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin.
Wren AM , Small CJ , Abbott CR , Dhillo WS , Seal LJ , Cohen MA , Batterham RL , Taheri S , Stanley SA , Ghatei MA , Bloom SR Ghrelin causes hyperphagia and obesity in rats. Tschöp M , Smiley DL , Heiman ML Ghrelin induces adiposity in rodents.
Drazen DL , Vahl TP , D'Alessio DA , Seeley RJ , Woods SC Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status.
Endocrinology : 23 — Cummings DE , Clement K , Purnell JQ , Vaisse C , Foster KE , Frayo RS , Schwartz MW , Basdevant A , Weigle DS Elevated plasma ghrelin levels in Prader Willi syndrome.
Nat Med 8 : — Cowley MA , Smith RG , Diano S , Tschop M , Pronchuk N , Grove KL , Strasburger CJ , Bidlingmaier M , Esterman M , Heiman ML , Garcia-Segura LM , Nillni EA , Mendez P , Low MJ , Sotonyi P , Friedman JM , Liu H , Pinto S , Colmers WF , Cone RD , Horvath TL The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis.
Neuron 37 : — Lawrence CB , Snape AC , Baudoin FM , Luckman SM Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Cummings DE Ghrelin and the short- and long-term regulation of appetite and body weight.
Physiol Behav 89 : 71 — Traebert M , Riediger T , Whitebread S , Scharrer E , Schmid HA Ghrelin acts on leptin-responsive neurones in the rat arcuate nucleus.
J Neuroendocrinol 14 : — Date Y , Murakami N , Toshinai K , Matsukura S , Niijima A , Matsuo H , Kangawa K , Nakazato M The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats.
Arnold M , Mura A , Langhans W , Geary N Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J Neurosci 26 : — Adolph EF Urges to eat and drink in rats.
Am J Physiol : — Janowitz HD , Grossman MI Effect of variations in nutritive density of food in dogs and rats. Woods SC , Strubbe JH The psychobiology of meals. Psychon Bull Rev 1 : — McLaughlin CL , Baile CA Cholecystokinin, amphetamine and diazepam and feeding in lean and obese Zucker rats.
Pharmacol Biochem Behav 10 : 87 — Niederau C , Meereis-Schwanke K , Klonowski-Stumpe H , Herberg L CCK resistance in Zucker obese versus lean rats. Regul Pept 70 : 97 — Kulkosky PJ , Breckenridge C , Krinsky R , Woods SC Satiety elicited by the C-terminal octapeptide of cholecystokinin-pancreozymin in normal and VMH-lesioned rats.
Behav Biol 18 : — Peptides 25 : — Peptides 2 : 39 — Pi-Sunyer X , Kissileff HR , Thornton J , Smith GP C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Williams DL , Baskin DG , Schwartz MW Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation.
Diabetes 55 : — West DB , Greenwood MRC , Marshall KA , Woods SC Lithium chloride, cholecystokinin and meal patterns: evidence the cholecystokinin suppresses meal size in rats without causing malaise.
Appetite 8 : — West DB , Williams RH , Braget DJ , Woods SC Bombesin reduces food intake of normal and hypothalamically obese rats and lowers body weight when given chronically. Peptides 3 : 61 — D'Alessio DA , Vahl TP Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
D'Alessio DA , Vahl TP Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. Curr Diab Rep 5 : — Buse JB , Klonoff DC , Nielsen LL , Guan X , Bowlus CL , Holcombe JH , Maggs DG , Wintle ME Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Clin Ther 29 : — Poon T , Nelson P , Shen L , Mihm M , Taylor K , Fineman M , Kim D Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.
Diabetes Technol Ther 7 : — Banks WA The blood-brain barrier as a regulatory interface in the gut-brain axes. Woods SC , Seeley RJ , Baskin DG , Schwartz MW Insulin and the blood-brain barrier. Curr Pharm Des 9 : — Benoit SC , Clegg DJ , Seeley RJ , Woods SC Insulin and leptin as adiposity signals.
Recent Prog Horm Res 59 : — Friedman JM The function of leptin in nutrition, weight, and physiology. Nutr Rev S1—S14; discussion S 84 : 85 — Seeley RJ , Woods SC Monitoring of stored and available fuel by the CNS: implications for obesity.
Nat Rev Neurosci 4 : — Grossman SP The role of glucose, insulin and glucagon in the regulation of food intake and body weight.
Neurosci Biobehav Rev 10 : — Langhans W Metabolic and glucostatic control of feeding. Proc Nutr Soc 55 : — Lotter EC , Woods SC Injections of insulin and changes of body weight. Physiol Behav 18 : — Nicolaidis S , Rowland N Metering of intravenous versus oral nutrients and regulation of energy balance.
Vanderweele DA , Haraczkiewicz E , Van Itallie TB Elevated insulin and satiety in obese and normal weight rats. Appetite 3 : 99 — Hallschmid M , Benedict C , Schultes B , Fehm HL , Born J , Kern W Intranasal insulin reduces body fat in men but not in women.
Diabetes 53 : — Hallschmid M , Benedict C , Born J , Fehm HL , Kern W Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiol Behav 83 : 55 — Lee JH , Chan JL , Sourlas E , Raptopoulos V , Mantzoros CS Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
J Clin Endocrinol Metab 91 : — Javor ED , Cochran EK , Musso C , Young JR , Depaoli AM , Gorden P Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.
Diabetes 54 : — Israel PA , Park CR , Schwartz MW , Green PK , Sipols AJ , Woods SC , Porte Jr D , Figewicz DP Effect of diet-induced obesity and experimental hyperinsulinemia on insulin uptake into CSF of the rat. Brain Res Bull 30 : — Owen OE , Reichard GAJ , Boden G , Shuman C Comparative measurements of glucose, β-hydroxybutyrate, acetoacetate, and insulin in blood and cerebrospinal fluid during starvation.
Metabolism 23 : 7 — Stein LJ , Dorsa DM , Baskin DG , Figlewicz DP , Ikeda H , Frankmann SP , Greenwood MR , Porte Jr D , Woods SC Immunoreactive insulin levels are elevated in the cerebrospinal fluid of genetically obese Zucker rats.
Ikeda H , West DB , Pustek JJ , Figlewicz DP , Greenwood MRC , Porte Jr D , Woods SC Intraventricular insulin reduces food intake and body weight of lean but not obese Zucker rats.
Appetite 7 : — Woods SC , D'Alessio DA , Tso P , Rushing PA , Clegg DJ , Benoit SC , Gotoh K , Liu M , Seeley RJ Consumption of a high-fat diet alters the homeostatic regulation of energy balance.
Cota D , Matter EK , Woods SC , Seeley RJ The role of hypothalamic mTORC1 signaling in diet-induced obesity.
J Neurosci 28 : — Air EL , Strowski MZ , Benoit SC , Conarello SL , Salituro GM , Guan XM , Liu K , Woods SC , Zhang BB Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity.
Zhang B , Salituro G , Szalkowski D , Li Z , Zhang Y , Royo I , Vilella D , Diez MT , Pelaez F , Ruby C , Kendall RL , Mao X , Griffin P , Calaycay J , Zierath JR , Heck JV , Smith RG , Moller DE Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.
Cone RD , Cowley MA , Butler AA , Fan W , Marks DL , Low MJ The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 25 Suppl 5 : S63 — S Peruzzo B , Pastor FE , Blazquez JL , Schobitz K , Pelaez B , Amat P , Rodriguez EM A second look at the barriers of the medial basal hypothalamus.
Exp Brain Res : 10 — Ahima RS , Saper CB , Flier JS , Elmquist JK Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 21 : — Cone RD Anatomy and regulation of the central melanocortin system.
Nat Neurosci 8 : — Elmquist JK , Coppari R , Balthasar N , Ichinose M , Lowell BB Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol : 63 — Schwartz MW , Porte Jr D Diabetes, obesity, and the brain.
Morton GJ , Cummings DE , Baskin DG , Barsh GS , Schwartz MW Central nervous system control of food intake and body weight. Benoit SC , Air EL , Coolen LM , Strauss R , Jackman A , Clegg DJ , Seeley RJ , Woods SC The catabolic action of insulin in the brain is mediated by melanocortins.
Seeley R , Yagaloff K , Fisher S , Burn P , Thiele T , van DG , Baskin D , Schwartz M Melanocortin receptors in leptin effects.
Nature : Stanley BG , Leibowitz SF Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sciences 35 : — Clark JT , Kalra PS , Crowley WR , Kalra SP Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats.
Corp ES , Melville LD , Greenberg D , Gibbs J , Smith GP Effect of fourth ventricular neuropeptide Y and peptide YY on ingestive and other behaviors. Zarjevski N , Cusin I , Vetter R , Rohner-Jeanrenaud F , Jeanrenaud B Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity.
Wilson BD , Ollmann MM , Barsh GS The role of agouti-related protein in regulating body weight. Mol Med Today 5 : — Vettor R , Zarjevski N , Cusin I , Johner-Jeanrenaud F , Jeanrenaud B Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats.
Diabetologia 37 : — Ollmann M , Wilson B , Yang Y , Kerns J , Chen Y , Gantz I , Barsh G Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Hagan MM , Rushing PA , Pritchard LM , Schwartz MW , Strack AM , Van der Ploeg HT , Woods SC , Seeley RJ Long-term orexigenic effects of AgRP- 83— involve mechanisms other than melanocortin receptor blockade.
Am J Physiol : R47 — R Hagan MM , Benoit SC , Rushing PA , Pritchard LM , Woods SC , Seeley RJ Immediate and prolonged patterns of agouti-related peptide- 83— -induced c-Fos activation in hypothalamic and extrahypothalamic sites.
Porte Jr D , Baskin DG , Schwartz MW Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C.
elegans to humans. Schwartz MW Central nervous system regulation of food intake. Obesity Silver Spring 14 Suppl 1 : 1S — 8S. Woods SC , Seeley RJ , Cota D Regulation of food intake through hypothalamic signaling networks involving mTOR.
Annu Rev Nutr 28 : — Berthoud HR Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 26 : — Levin BE Metabolic sensing neurons and the control of energy homeostasis. Lam TK , Pocai A , Gutierrez-Juarez R , Obici S , Bryan J , Aguilar-Bryan L , Schwartz GJ , Rossetti L Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis.
Nat Med 11 : — Obici S , Feng Z , Morgan K , Stein D , Karkanias G , Rossetti L Central administration of oleic acid inhibits glucose production and food intake. Diabetes 51 : — Cota D , Proulx K , Woods SC , Seeley RJ Role of leucine in regulating food intake.
Cota D , Proulx K , Seeley RJ The role of CNS fuel sensing in energy and glucose regulation. Seeley RJ , York DA Fuel sensing and the central nervous system CNS : implications for the regulation of energy balance and the treatment for obesity.
Obes Rev 6 : — Fehm HL , Kern W , Peters A The selfish brain: competition for energy resources. Prog Brain Res : — Berthoud HR Homeostatic and non-homeostatic pathways involved in the control of food intake and energy balance. Obesity Silver Spring 14 Suppl 5 : S — S. Grill HJ , Kaplan JM The neuroanatomical axis for control of energy balance.
Front Neuroendocrinol 23 : 2 — Schwartz GJ Integrative capacity of the caudal brainstem in the control of food intake. Richard D , Huang Q , Timofeeva E The corticotropin-releasing hormone system in the regulation of energy balance in obesity.
Int J Obes Relat Metab Disord 24 : S36 — S Verbalis JG , Blackburn RE , Olson BR , Stricker EM Central oxytocin inhibition of food and salt ingestion: a mechanism for intake regulation of solute homeostasis.
Regul Pept 45 : — Qu D , Ludwig DS , Gammeltoft S , Piper M , Pelleymounter MA , Cullen MJ , Mathes WF , Przypek R , Kanarek R , Maratos-Flier E A role for melanin-concentrating hormone in the central regulation of feeding behaviour.
Nahon JL The melanocortins and melanin-concentrating hormone in the central regulation of feeding behavior and energy homeostasis. C R Biol —; discussion — Sweet DC , Levine AS , Billington CJ , Kotz CM Feeding response to central orexins. Strubbe JH , van Dijk G The temporal organization of ingestive behaviour and its interaction with regulation of energy balance.
Matson CA , Wiater MF , Kuijper JL , Weigle DS Synergy between leptin and cholecystokinin CCK to control daily caloric intake. Peptides 18 : — Matson CA , Ritter RC Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight.
Riedy CA , Chavez M , Figlewicz DP , Woods SC Central insulin enhances sensitivity to cholecystokinin. Emond M , Schwartz GJ , Ladenheim EE , Moran TH Central leptin modulates behavioral and neural responsivity to CCK.
Figlewicz DP , Stein LJ , West D , Porte Jr D , Woods SC Intracisternal insulin alters sensitivity to CCK-induced meal suppression in baboons. Ladenheim EE , Emond M , Moran TH Leptin enhances feeding suppression and neural activation produced by systemically administered bombesin.
Morton GJ , Blevins JE , Williams DL , Niswender KD , Gelling RW , Rhodes CJ , Baskin DG , Schwartz MW Leptin action in the forebrain regulates the hindbrain response to satiety signals.
McMinn JE , Sindelar DK , Havel PJ , Schwartz MW Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin. Grill HJ , Smith GP Cholecystokinin decreases sucrose intake in chronic decerebrate rats.
Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Endocrine Society Journals. Advanced Search. Search Menu.
Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents ABSTRACT. Satiation Signals. Adiposity Signals. Central Integrating Circuits. Integration of Satiation and Adiposity Signals. Journal Article.
Central Control of Body Weight and Appetite. Woods , Stephen C. Woods, Department of Psychiatry, University of Cincinnati, East Galbraith Road, Cincinnati, Ohio Oxford Academic.
David A. PDF Split View Views. Cite Cite Stephen C. Select Format Select format. ris Mendeley, Papers, Zotero. enw EndNote. bibtex BibTex. txt Medlars, RefWorks Download citation. Permissions Icon Permissions. ABSTRACT Context.
Open in new tab Download slide. TABLE 1. GI hormones that affect satiation. Effect on food intake. Open in new tab. α-melanocyte-stimulating hormone;. Google Scholar PubMed. OpenURL Placeholder Text. Google Scholar Crossref. Search ADS. Google Scholar OpenURL Placeholder Text. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects.
Prolonged mild hyperglycemia induces vagally mediated compensatory increase in C-peptide secretion in humans. Oxford, UK: Oxford University Press;.
Relationships between gastric motility and gastric vagal afferent responses to CCK and GRP in rats differ. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin.
Food-related gastrointestinal signals activate caudal brainstem neurons expressing both NMDA and AMPA receptors.
Cholecystokinin activates catecholaminergic neurons in the caudal medulla that innervate the paraventricular nucleus of the hypothalamus in rats.
Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. The cholecystokinin receptor antagonist L, increases food intake in the rat by attenuation of endogenous cholecystokinin. Potent cholecystokinin antagonist L, stimulates food intake in rats.
Rapid development of tolerance to the behavioural actions of cholecystokinin. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Interaction between GLP-1 and CCK in inhibiting food intake and appetite in men.
Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.
Gene structure of human cholecystokinin CCK type-A receptor: body fat content is related to CCK type-A receptor gene promoter polymorphism. Nutrient, neural and endocrine control of glucagon-like peptide secretion.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Glucagonlike peptide-1 GLP-1 participation in ileal brake induced by intraluminal peptones in rat.
Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Dipeptidyl-peptidase IV CD26 —role in the inactivation of regulatory peptides.
Effects of GLP 7—36 NH2, GLP 7—37 , and GLP 9—36 NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.
Role of central nervous system glucagon-like peptide-1 receptors in enteric glucosesensing. Glucagon-like peptide-1 GLP-1 receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
Central administration of GLP 7—36 amide inhibits food and water intake in rats. A role for glucagon-like peptide-1 in the central regulation of feeding {lsqb;see comments{rsqb;. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.
Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Central infusion of leptin and GLP-1 7—36 amide differentially stimulate c-Fos-like immunoreactivity in the rat brain. Colocalization of glucagon-like peptide-1 GLP-1 receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake.
The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 7—36 amide.
PVN infusion of GLP-1 7—36 amide suppresses feeding and drinking but does not induce conditioned taste aversions or alter locomotion in rats.
The role of CNS GLP 7—36 amide receptors in mediating the visceral illness effects of lithium chloride. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. Energy intake and appetite are suppressed by glucagon-like peptide-1 GLP-1 in obese men.
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Interactions of glucagon-like peptide-1 GLP-1 with the blood-brain barrier. GLPbased therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction.
Dipeptidyl peptidase IV DPP IV and related molecules in type 2 diabetes. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Peripheral oxyntomodulin reduces food intake and body weight gain in rats.
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. The role of oxyntomodulin and peptide tyrosine-tyrosine PYY in appetite control. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats.
Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake.
Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. New York: Oxford University Press;. Pancreatic signals controlling food intake; insulin, glucagon, and amylin.
Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Stimulation of feeding in rats by intraperitoneal injection of antibodies to glucagon. Hepatic portal infusion of glucagon antibodies increases spontaneous meal size in rats.
Two molecular forms of peptide YY PYY are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1—36 and PYY 3— Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV.
Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3— The ileal brake—inhibition of jejunal motility after ileal fat perfusion in man.
Characterization of blood-brain barrier permeability to PYY3—36 in mouse. Attenuated peptide YY release in obese subjects is associated with reduced satiety.
Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents.
Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men. Intestinal satiety protein apolipoprotein AIV is synthesized and regulated in rat hypothalamus.
Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. Effect of intravenous administration of apolipoprotein A-IV on patterns of feeding, drinking and ambulatory activity in rats.
Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake. Neuropeptide Y and lipid increase apolipoprotein AIV gene expression in rat hypothalamus. Enterostatin Val-Pro-Asp-Pro-Arg , the activation peptide of procolipase, selectively reduces fat intake.
Enterostatin suppresses food intake following injection into the third ventricle of rats. Effect of enterostatin given intravenously and intracerebroventricularly on high-fat feeding in rats.
Differential inhibition of fat intake in two strains of rat by the peptide enterostatin. Receptor subtype mediation of feeding suppression by bombesin-like peptides. Disruptions in feeding and body weight control in gastrin-releasing peptide receptor deficient mice. Prolongation of the postprandial intermeal interval by gastrin-releasing peptide 1—27 in spontaneously feeding rats.
Bombesin reduces food intake in lean man by a cholecystokinin-independent mechanism. Effect of intravenous human gastrin-releasing peptide on food intake in humans. Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist.
Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit. Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Inhibition of central amylin signaling increases food intake and body adiposity in rats.
Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic β-cells. Novel receptor partners and function of receptor activity-modifying proteins. Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin.
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Within in hypothalamus lies the arcuate nucleus, which plays a key role in the control of appetite. The appetite centre contains both primary and secondary neurones. The primary neurones process external signals, be it neuronal, hormonal or nutritional. The secondary neurones are then responsible for co-ordinating the inputs received via the primary neurone.
These primary neurones are either excitatory or inhibitory. The neurotransmitters released by excitatory and inhibitory neurones are:. Ghrelin is a peptide hormone produced in the pancreas and released from the stomach wall when the stomach is empty.
This stimulates the excitatory primary neurones, and therefore stimulates appetite. When the stomach is full, ghrelin release is inhibited, thus the appetite stimulus is also inhibited. PYY full name — peptide tyrosine tyrosine is a short peptide hormone released by cells in the ileum and colon in response to feeding.
It inhibits the excitatory primary neurones of the arcuate nucleus. This causes appetite suppression. Leptin is a peptide hormone released into the blood by adipocytes fat cells.
Leptin stimulates the inhibitory neurones and inhibits the excitatory neurones in the arcuate nucleus to cause suppression of appetite. Insulin is a hormone released from beta cells in the islets of Langerhans of the pancreas. This suppresses appetite in a similar way to leptin.
Leptin deficiency may arise from deletion of the leptin gene causing severe obesity, hyperphagia excessive eating and a reduced metabolic rate. However, this is incredibly rare. Leptin deficiency can also be found in conditions and syndromes where there is significant lipodystrophy.
The effects of leptin deficiency can be reversed with the use of exogenous leptin. PYY full name - peptide tyrosine tyrosine is a short peptide hormone released by cells in the ileum and colon in response to feeding. Once you've finished editing, click 'Submit for Review', and your changes will be reviewed by our team before publishing on the site.
We use cookies to improve your experience on our site and to show you relevant advertising. To find out more, read our privacy policy.
Appetite Home Gastrointestinal The Stomach Appetite. star star star star star. Appetite Control Centre The appetite control centre is located in the hypothalamus. The neurotransmitters released by excitatory and inhibitory neurones are: Excitatory: Neuropeptide Y NPY and Agouti-related peptide AgRP.
Original Author s : Ankita Kochhar Last Prestigious 16th July Revisions: Appetite control system In order to Appetitte that we dontrol to eat food to Appetite control system zystem bodies, Sports supplementation experience the sensation of hunger. In this article, Sports supplementation will look at the key signals involved in the control of appetite, including those that promote hunger and those that cause satiety. The appetite control centre is located in the hypothalamus. Within in hypothalamus lies the arcuate nucleus, which plays a key role in the control of appetite. The appetite centre contains both primary and secondary neurones. The primary neurones process external signals, be it neuronal, hormonal or nutritional. Body weight Recovery coaching services mainly influenced ocntrol your appetite the Contrkl to Sports supplementation and satiety the sensation of fullness. Many signaling molecules and hormones control cojtrol and satiety in Sports and energy expenditure Appetite control system, peripheral and Apletite nervous systems. The Sports supplementation variants involved in overweight and obesity are often associated with increased appetite or diminished satiety. Body weight is determined by energy balance. The calories you get from food and beverages are called your energy intake while the calories you expend to support your life and daily activities are called your energy expenditure. When energy intake equals energy expenditure, your body weight remains the same but when energy intake exceeds your energy expenditure then you have an energy surplus. Excess energy is stored in your body as fat resulting in weight gain.Video
Leptin and Ghrelin hormones mechanism of action - Physiology : USMLE Step 1Appetite control system -
This prohormone is processed post-translation by a series of cleavages and amino acid modifications in a tissue-specific manner, resulting in different POMC peptides by different cell types. Its main function in the hypothalamus is to stimulate anorexigenic neurons to suppress appetite.
First discovered as a respondent to cocaine and amphetamine administration, CART is believed to play roles in reward and addiction regulations. Melanin-concentrating hormone MCH is a signaling peptide 19 amino acids expressed in a discrete population of neurons in the hypothalamus.
MCH receptors are expressed in the NAcc, amygdala, and hypothalamus. It is hypothesized that MCH mediates the appetite-stimulating effects in response to taste and olfactory signals. The MCH neuron also interacts with the opioid systems, suggesting a connection with the hedonic system. Orexins include two peptides, OX-A and OX-B, and each interacts with its own G-protein coupled receptors.
The OX-A receptor is OX-1 and the OX-B receptor is OX Orexin neurons are stimulated by lower plasma glucose levels and inhibited by high glucose levels. Orexin is believed to modulate glucose homeostasis by initiating and terminating eating episodes.
Orexins are also thought to play a role in reward systems through interaction with dopamine neurons. CRH corticotropin-releasing hormone and TRH thyrotropin-releasing hormone are hormones that trigger the release of many down-stream hormones in the pituitary gland. These down-stream hormones regulate many physiological processes including energy homeostasis and stress response.
Opioids and cannabinoids are the primary hedonic signals that stimulate appetite. Three opioid receptors μ-, δ-, and κ- are responsible for the reward system stimulation by palatable tastes and smells.
The opioid receptor antagonist naloxone reduces the consumption of sweet, high-fat foods while another opioid receptor antagonist naltrexone reduces preference for sucrose. The cannabinoid receptor CB1 is responsible for the cravings for fattening foods. An endogenous CB1 ligand anandamide induces overeating while a CB1 antagonist rimonabant can reduce food intake and body weight by selectively inhibiting consumption of palatable foods.
Serotonin 5-HT is a neurotransmitter derived from the amino acid tryptophan. Serotonin suppresses appetite through numerous processes involving over 15 receptors. Although the majority of serotonin in the human body is produced in the gut, a small quantity produced in the CNS is thought to be critical for the regulation of mood and sleep as well as appetite.
Body weight is determined by the balance in energy intake and energy consumption. Excess energy intake is the major cause of overweight and obesity in the United States.
Most known obesity risk genes are involved in appetite control systems in the CNS and peripheral signaling. Therefore, the most effective measure to combat overweight and obesity in the general population is calorie restriction.
For those who carry risk genes for energy intake, being conscious of your food intake is especially important. Batterham RL, Ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ, Williams SC.
PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. PMID 2. Blundell JE, Caudwell P, Gibbons C, Hopkins M, Naslund E, King N, Finlayson G. Role of resting metabolic rate and energy expenditure in hunger and appetite control: a new formulation.
Dis Model Mech. doi: PMID 3. Castañeda TR, Tong J, Datta R, Culler M, Tschöp MH. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol. Deshaies Y. AMP kinase: heart, cancer and the CNS--view from the chair.
Int J Obes Lond. PMID 5. Dockray GJ. CurrOpinEndocrinol Diabetes Obes. PMID 6. Dong CX, Brubaker PL. Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis. Nat Rev GastroenterolHepatol.
PMID: 7. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Suppl 4:S PMID 8.
Harrold JA, Dovey TM, Blundell JE, Halford JC. CNS regulation of appetite. PMID 9. Li J, McCullough LD. Effects of AMP-activated protein kinase in cerebral ischemia. J Cereb Blood Flow Metab.
Epub Dec PMID Rehfeld JF, Sun G, Christensen T, Hillingsø JG. The predominant cholecystokinin in human plasma and intestine is cholecystokinin J ClinEndocrinolMetab. Schellekens H, Finger BC, Dinan TG, Cryan JF. Ghrelin signalling and obesity: at the interface of stress, mood and food reward.
Zhang, J. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science PubMed: About Us Press Releases Contact Us. It is not a substitute for professional medical advice, diagnosis or treatment.
Never stop or delay seeking treatment because of something you have read on the GB HealthWatch website. GB HealthWatch urges you to consult with a qualified physician for diagnosis and for answers to your personal health questions.
If you think you may have a medical emergency, call your doctor or immediately. HealthWatch app HealthWatch web HealthWatch Wellness HealthWatch Research GBinsight Genetic Analysis Weight Control Diet Evaluator BMI Calculator Fitness Trackers more reviews and comments.
Food-Fitness Genes-Nutrition-Disease Health Hot Topics. Disease A-Z Nutrition A-Z Connect Your Genes. HealthWatch - the best Gene Nutrition Health Tracker App. Free - In Google Play. genetic testing. healthwatch research portal. sign in. Your session has timed out. Please log in again. Don't have a GB account?
Register here. It's free and easy. forgot your password? Login with Facebook. GBinsight Genetic Analysis Healthwatch Research Portal. Share this page Connect your genes.
genes, nutrition, disease weight control science Body weight, appetite and satiety. select a topic:. DNA-based diet as medicine. alzheimer's disease. blood lipids. blood pressure. heart disease. Batterham RL , Bloom SR The gut hormone peptide YY regulates appetite.
Ann NY Acad Sci : — Degen L , Oesch S , Casanova M , Graf S , Ketterer S , Drewe J , Beglinger C Effect of peptide YY3—36 on food intake in humans. le Roux CW , Batterham RL , Aylwin SJ , Patterson M , Borg CM , Wynne KJ , Kent A , Vincent RP , Gardiner J , Ghatei MA , Bloom SR Attenuated peptide YY release in obese subjects is associated with reduced satiety.
Endocrinology : 3 — 8. Batterham RL , Cohen MA , Ellis SM , Le Roux CW , Withers DJ , Frost GS , Ghatei MA , Bloom SR Inhibition of food intake in obese subjects by peptide YY3— N Engl J Med : — Stock S , Leichner P , Wong AC , Ghatei MA , Kieffer TJ , Bloom SR , Chanoine JP Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents.
J Clin Endocrinol Metab 90 : — Lavebratt C , Alpman A , Persson B , Arner P , Hoffstedt J Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men. Ahituv N , Kavaslar N , Schackwitz W , Ustaszewska A , Collier JM , Hebert S , Doelle H , Dent R , Pennacchio LA , McPherson R A PYY Q62P variant linked to human obesity.
Hum Mol Genet 15 : — Tso P , Liu M , Kalogeris TJ , Thomson AB The role of apolipoprotein A-IV in the regulation of food intake.
Annu Rev Nutr 21 : — Liu M , Doi T , Shen L , Woods SC , Seeley RJ , Zheng S , Jackman A , Tso P Intestinal satiety protein apolipoprotein AIV is synthesized and regulated in rat hypothalamus. Fujimoto K , Fukagawa K , Sakata T , Tso P Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats.
J Clin Invest 91 : — Fujimoto K , Machidori H , Iwakiri R , Yamamoto K , Fujisaki J , Sakata T , Tso P Effect of intravenous administration of apolipoprotein A-IV on patterns of feeding, drinking and ambulatory activity in rats.
Lo CM , Zhang DM , Pearson K , Ma L , Sun W , Sakai RR , Davidson WS , Liu M , Raybould HE , Woods SC , Tso P Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake. Liu M , Shen L , Doi T , Woods SC , Seeley RJ , Tso P Neuropeptide Y and lipid increase apolipoprotein AIV gene expression in rat hypothalamus.
Tso P , Liu M Apolipoprotein A-IV, food intake, and obesity. Physiol Behav 83 : — Okada S , York DA , Bray GA , Erlanson-Albertsson C Enterostatin Val-Pro-Asp-Pro-Arg , the activation peptide of procolipase, selectively reduces fat intake.
Physiol Behav 49 : — Shargill NS , Tsuji S , Bray GA , Erlanson-Albertsson C Enterostatin suppresses food intake following injection into the third ventricle of rats. Mei J , Erlanson-Albertsson C Effect of enterostatin given intravenously and intracerebroventricularly on high-fat feeding in rats.
Regul Pept 41 : — Okada S , York DA , Bray GA , Mei J , Erlanson-Albertsson C Differential inhibition of fat intake in two strains of rat by the peptide enterostatin. Muurahainen NE , Kissileff HR , Pi-Sunyer FX Intravenous infusion of bombesin reduces food intake in humans.
Ladenheim EE , Wirth KE , Moran TH Receptor subtype mediation of feeding suppression by bombesin-like peptides. Pharmacol Biochem Behav 54 : — Stein LJ , Woods SC Gastrin releasing peptide reduces meal size in rats. Peptides 3 : — Ladenheim EE , Hampton LL , Whitney AC , White WO , Battey JF , Moran TH Disruptions in feeding and body weight control in gastrin-releasing peptide receptor deficient mice.
J Endocrinol : — Stuckey JA , Gibbs J , Smith GP Neural disconnection of gut from brain blocks bombesin-induced satiety. Peptides 6 : — Rushing PA , Henderson RP , Gibbs J Prolongation of the postprandial intermeal interval by gastrin-releasing peptide 1—27 in spontaneously feeding rats.
Peptides 19 : — Lieverse RJ , Jansen JB , van de Zwan A , Samson L , Masclee AA , Rovati LC , Lamers CB Bombesin reduces food intake in lean man by a cholecystokinin-independent mechanism. J Clin Endocrinol Metab 76 : — Gutzwiller JP , Drewe J , Hildebrand P , Rossi L , Lauper JZ , Beglinger C Effect of intravenous human gastrin-releasing peptide on food intake in humans.
Hildebrand P , Lehmann FS , Ketterer S , Christ AD , Stingelin T , Beltinger J , Gibbons AH , Coy DH , Calam J , Larsen F , Beglinger C Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist.
Degen LP , Peng F , Collet A , Rossi L , Ketterer S , Serrano Y , Larsen F , Beglinger C , Hildebrand P Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit. Ludvik B , Kautzky-Willer A , Prager R , Thomaseth K , Pacini G Amylin: history and overview.
Diabet Med 14 Suppl 2 : S9 — S Chance WT , Balasubramaniam A , Zhang FS , Wimalawansa SJ , Fischer JE Anorexia following the intrahypothalamic administration of amylin. Lutz TA Amylinergic control of food intake.
Physiol Behav 89 : — Lutz TA , Del Prete E , Scharrer E Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav 55 : — Lutz TA , Geary N , Szabady MM , Del Prete E , Scharrer E Amylin decreases meal size in rats.
Physiol Behav 58 : — Rushing PA , Hagan MM , Seeley RJ , Lutz TA , Woods SC Amylin: a novel action in the brain to reduce body weight. Rushing PA , Hagan MM , Seeley RJ , Lutz TA , D'Alessio DA , Air EL , Woods SC Inhibition of central amylin signaling increases food intake and body adiposity in rats.
Endocrinology : Martinez A , Kapas S , Miller MJ , Ward Y , Cuttitta F Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic β-cells.
Christopoulos A , Christopoulos G , Morfis M , Udawela M , Laburthe M , Couvineau A , Kuwasako K , Tilakaratne N , Sexton PM Novel receptor partners and function of receptor activity-modifying proteins.
J Biol Chem : — Rushing PA , Lutz TA , Seeley RJ , Woods SC Amylin and insulin interact to reduce food intake in rats. Horm Metab Res 32 : 62 — Mollet A , Meier S , Grabler V , Gilg S , Scharrer E , Lutz TA Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin.
Peptides 24 : 91 — Whitehouse F , Kruger DF , Fineman M , Shen L , Ruggles JA , Maggs DG , Weyer C , Kolterman OG A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Diabetes Care 25 : — Hollander PA , Levy P , Fineman MS , Maggs DG , Shen LZ , Strobel SA , Weyer C , Kolterman OG Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Diabetes Care 26 : — Wiedmer P , Nogueiras R , Broglio F , D'Alessio D , Tschop MH Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 3 : — Cummings DE , Purnell JQ , Frayo RS , Schmidova K , Wisse BE , Weigle DS A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.
Diabetes 50 : — Asakawa A , Inui A , Kaga T , Yuzuriha H , Nagata T , Ueno N , Makino S , Fujimiya M , Niijima A , Fujino MA , Kasuga M Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Wren AM , Small CJ , Abbott CR , Dhillo WS , Seal LJ , Cohen MA , Batterham RL , Taheri S , Stanley SA , Ghatei MA , Bloom SR Ghrelin causes hyperphagia and obesity in rats.
Tschöp M , Smiley DL , Heiman ML Ghrelin induces adiposity in rodents. Drazen DL , Vahl TP , D'Alessio DA , Seeley RJ , Woods SC Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status.
Endocrinology : 23 — Cummings DE , Clement K , Purnell JQ , Vaisse C , Foster KE , Frayo RS , Schwartz MW , Basdevant A , Weigle DS Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8 : — Cowley MA , Smith RG , Diano S , Tschop M , Pronchuk N , Grove KL , Strasburger CJ , Bidlingmaier M , Esterman M , Heiman ML , Garcia-Segura LM , Nillni EA , Mendez P , Low MJ , Sotonyi P , Friedman JM , Liu H , Pinto S , Colmers WF , Cone RD , Horvath TL The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis.
Neuron 37 : — Lawrence CB , Snape AC , Baudoin FM , Luckman SM Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers.
Cummings DE Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 89 : 71 — Traebert M , Riediger T , Whitebread S , Scharrer E , Schmid HA Ghrelin acts on leptin-responsive neurones in the rat arcuate nucleus. J Neuroendocrinol 14 : — Date Y , Murakami N , Toshinai K , Matsukura S , Niijima A , Matsuo H , Kangawa K , Nakazato M The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats.
Arnold M , Mura A , Langhans W , Geary N Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J Neurosci 26 : — Adolph EF Urges to eat and drink in rats.
Am J Physiol : — Janowitz HD , Grossman MI Effect of variations in nutritive density of food in dogs and rats. Woods SC , Strubbe JH The psychobiology of meals. Psychon Bull Rev 1 : — McLaughlin CL , Baile CA Cholecystokinin, amphetamine and diazepam and feeding in lean and obese Zucker rats.
Pharmacol Biochem Behav 10 : 87 — Niederau C , Meereis-Schwanke K , Klonowski-Stumpe H , Herberg L CCK resistance in Zucker obese versus lean rats. Regul Pept 70 : 97 — Kulkosky PJ , Breckenridge C , Krinsky R , Woods SC Satiety elicited by the C-terminal octapeptide of cholecystokinin-pancreozymin in normal and VMH-lesioned rats.
Behav Biol 18 : — Peptides 25 : — Peptides 2 : 39 — Pi-Sunyer X , Kissileff HR , Thornton J , Smith GP C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Williams DL , Baskin DG , Schwartz MW Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation.
Diabetes 55 : — West DB , Greenwood MRC , Marshall KA , Woods SC Lithium chloride, cholecystokinin and meal patterns: evidence the cholecystokinin suppresses meal size in rats without causing malaise.
Appetite 8 : — West DB , Williams RH , Braget DJ , Woods SC Bombesin reduces food intake of normal and hypothalamically obese rats and lowers body weight when given chronically. Peptides 3 : 61 — D'Alessio DA , Vahl TP Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
D'Alessio DA , Vahl TP Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.
Curr Diab Rep 5 : — Buse JB , Klonoff DC , Nielsen LL , Guan X , Bowlus CL , Holcombe JH , Maggs DG , Wintle ME Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Clin Ther 29 : — Poon T , Nelson P , Shen L , Mihm M , Taylor K , Fineman M , Kim D Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.
Diabetes Technol Ther 7 : — Banks WA The blood-brain barrier as a regulatory interface in the gut-brain axes. Woods SC , Seeley RJ , Baskin DG , Schwartz MW Insulin and the blood-brain barrier.
Curr Pharm Des 9 : — Benoit SC , Clegg DJ , Seeley RJ , Woods SC Insulin and leptin as adiposity signals. Recent Prog Horm Res 59 : — Friedman JM The function of leptin in nutrition, weight, and physiology.
Nutr Rev S1—S14; discussion S 84 : 85 — Seeley RJ , Woods SC Monitoring of stored and available fuel by the CNS: implications for obesity. Nat Rev Neurosci 4 : — Grossman SP The role of glucose, insulin and glucagon in the regulation of food intake and body weight.
Neurosci Biobehav Rev 10 : — Langhans W Metabolic and glucostatic control of feeding. Proc Nutr Soc 55 : — Lotter EC , Woods SC Injections of insulin and changes of body weight.
Physiol Behav 18 : — Nicolaidis S , Rowland N Metering of intravenous versus oral nutrients and regulation of energy balance. Vanderweele DA , Haraczkiewicz E , Van Itallie TB Elevated insulin and satiety in obese and normal weight rats.
Appetite 3 : 99 — Hallschmid M , Benedict C , Schultes B , Fehm HL , Born J , Kern W Intranasal insulin reduces body fat in men but not in women.
Diabetes 53 : — Hallschmid M , Benedict C , Born J , Fehm HL , Kern W Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiol Behav 83 : 55 — Lee JH , Chan JL , Sourlas E , Raptopoulos V , Mantzoros CS Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
J Clin Endocrinol Metab 91 : — Javor ED , Cochran EK , Musso C , Young JR , Depaoli AM , Gorden P Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54 : — Israel PA , Park CR , Schwartz MW , Green PK , Sipols AJ , Woods SC , Porte Jr D , Figewicz DP Effect of diet-induced obesity and experimental hyperinsulinemia on insulin uptake into CSF of the rat.
Brain Res Bull 30 : — Owen OE , Reichard GAJ , Boden G , Shuman C Comparative measurements of glucose, β-hydroxybutyrate, acetoacetate, and insulin in blood and cerebrospinal fluid during starvation. Metabolism 23 : 7 — Stein LJ , Dorsa DM , Baskin DG , Figlewicz DP , Ikeda H , Frankmann SP , Greenwood MR , Porte Jr D , Woods SC Immunoreactive insulin levels are elevated in the cerebrospinal fluid of genetically obese Zucker rats.
Ikeda H , West DB , Pustek JJ , Figlewicz DP , Greenwood MRC , Porte Jr D , Woods SC Intraventricular insulin reduces food intake and body weight of lean but not obese Zucker rats.
Appetite 7 : — Woods SC , D'Alessio DA , Tso P , Rushing PA , Clegg DJ , Benoit SC , Gotoh K , Liu M , Seeley RJ Consumption of a high-fat diet alters the homeostatic regulation of energy balance.
Cota D , Matter EK , Woods SC , Seeley RJ The role of hypothalamic mTORC1 signaling in diet-induced obesity. J Neurosci 28 : — Air EL , Strowski MZ , Benoit SC , Conarello SL , Salituro GM , Guan XM , Liu K , Woods SC , Zhang BB Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity.
Zhang B , Salituro G , Szalkowski D , Li Z , Zhang Y , Royo I , Vilella D , Diez MT , Pelaez F , Ruby C , Kendall RL , Mao X , Griffin P , Calaycay J , Zierath JR , Heck JV , Smith RG , Moller DE Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.
Cone RD , Cowley MA , Butler AA , Fan W , Marks DL , Low MJ The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis.
Int J Obes Relat Metab Disord 25 Suppl 5 : S63 — S Peruzzo B , Pastor FE , Blazquez JL , Schobitz K , Pelaez B , Amat P , Rodriguez EM A second look at the barriers of the medial basal hypothalamus. Exp Brain Res : 10 — Ahima RS , Saper CB , Flier JS , Elmquist JK Leptin regulation of neuroendocrine systems.
Front Neuroendocrinol 21 : — Cone RD Anatomy and regulation of the central melanocortin system. Nat Neurosci 8 : — Elmquist JK , Coppari R , Balthasar N , Ichinose M , Lowell BB Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis.
J Comp Neurol : 63 — Schwartz MW , Porte Jr D Diabetes, obesity, and the brain. Morton GJ , Cummings DE , Baskin DG , Barsh GS , Schwartz MW Central nervous system control of food intake and body weight.
Benoit SC , Air EL , Coolen LM , Strauss R , Jackman A , Clegg DJ , Seeley RJ , Woods SC The catabolic action of insulin in the brain is mediated by melanocortins. Seeley R , Yagaloff K , Fisher S , Burn P , Thiele T , van DG , Baskin D , Schwartz M Melanocortin receptors in leptin effects.
Nature : Stanley BG , Leibowitz SF Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus.
Life Sciences 35 : — Clark JT , Kalra PS , Crowley WR , Kalra SP Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Corp ES , Melville LD , Greenberg D , Gibbs J , Smith GP Effect of fourth ventricular neuropeptide Y and peptide YY on ingestive and other behaviors.
Zarjevski N , Cusin I , Vetter R , Rohner-Jeanrenaud F , Jeanrenaud B Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity.
Wilson BD , Ollmann MM , Barsh GS The role of agouti-related protein in regulating body weight. Mol Med Today 5 : — Vettor R , Zarjevski N , Cusin I , Johner-Jeanrenaud F , Jeanrenaud B Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats.
Diabetologia 37 : — Ollmann M , Wilson B , Yang Y , Kerns J , Chen Y , Gantz I , Barsh G Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Hagan MM , Rushing PA , Pritchard LM , Schwartz MW , Strack AM , Van der Ploeg HT , Woods SC , Seeley RJ Long-term orexigenic effects of AgRP- 83— involve mechanisms other than melanocortin receptor blockade.
Am J Physiol : R47 — R Hagan MM , Benoit SC , Rushing PA , Pritchard LM , Woods SC , Seeley RJ Immediate and prolonged patterns of agouti-related peptide- 83— -induced c-Fos activation in hypothalamic and extrahypothalamic sites. Porte Jr D , Baskin DG , Schwartz MW Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C.
elegans to humans. Schwartz MW Central nervous system regulation of food intake. Obesity Silver Spring 14 Suppl 1 : 1S — 8S. Woods SC , Seeley RJ , Cota D Regulation of food intake through hypothalamic signaling networks involving mTOR.
Annu Rev Nutr 28 : — Berthoud HR Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 26 : — Levin BE Metabolic sensing neurons and the control of energy homeostasis.
Lam TK , Pocai A , Gutierrez-Juarez R , Obici S , Bryan J , Aguilar-Bryan L , Schwartz GJ , Rossetti L Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 11 : — Obici S , Feng Z , Morgan K , Stein D , Karkanias G , Rossetti L Central administration of oleic acid inhibits glucose production and food intake.
Diabetes 51 : — Cota D , Proulx K , Woods SC , Seeley RJ Role of leucine in regulating food intake. Cota D , Proulx K , Seeley RJ The role of CNS fuel sensing in energy and glucose regulation.
Seeley RJ , York DA Fuel sensing and the central nervous system CNS : implications for the regulation of energy balance and the treatment for obesity. Obes Rev 6 : — Fehm HL , Kern W , Peters A The selfish brain: competition for energy resources.
Prog Brain Res : — Berthoud HR Homeostatic and non-homeostatic pathways involved in the control of food intake and energy balance. Obesity Silver Spring 14 Suppl 5 : S — S.
Grill HJ , Kaplan JM The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 23 : 2 — Schwartz GJ Integrative capacity of the caudal brainstem in the control of food intake.
Richard D , Huang Q , Timofeeva E The corticotropin-releasing hormone system in the regulation of energy balance in obesity. Int J Obes Relat Metab Disord 24 : S36 — S Verbalis JG , Blackburn RE , Olson BR , Stricker EM Central oxytocin inhibition of food and salt ingestion: a mechanism for intake regulation of solute homeostasis.
Regul Pept 45 : — Qu D , Ludwig DS , Gammeltoft S , Piper M , Pelleymounter MA , Cullen MJ , Mathes WF , Przypek R , Kanarek R , Maratos-Flier E A role for melanin-concentrating hormone in the central regulation of feeding behaviour.
Nahon JL The melanocortins and melanin-concentrating hormone in the central regulation of feeding behavior and energy homeostasis.
C R Biol —; discussion — Sweet DC , Levine AS , Billington CJ , Kotz CM Feeding response to central orexins.
Strubbe JH , van Dijk G The temporal organization of ingestive behaviour and its interaction with regulation of energy balance. Matson CA , Wiater MF , Kuijper JL , Weigle DS Synergy between leptin and cholecystokinin CCK to control daily caloric intake.
Peptides 18 : — Matson CA , Ritter RC Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight. Riedy CA , Chavez M , Figlewicz DP , Woods SC Central insulin enhances sensitivity to cholecystokinin. Emond M , Schwartz GJ , Ladenheim EE , Moran TH Central leptin modulates behavioral and neural responsivity to CCK.
Figlewicz DP , Stein LJ , West D , Porte Jr D , Woods SC Intracisternal insulin alters sensitivity to CCK-induced meal suppression in baboons. Ladenheim EE , Emond M , Moran TH Leptin enhances feeding suppression and neural activation produced by systemically administered bombesin.
Morton GJ , Blevins JE , Williams DL , Niswender KD , Gelling RW , Rhodes CJ , Baskin DG , Schwartz MW Leptin action in the forebrain regulates the hindbrain response to satiety signals.
McMinn JE , Sindelar DK , Havel PJ , Schwartz MW Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin.
Grill HJ , Smith GP Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
Sign In or Create an Account. Endocrine Society Journals. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents ABSTRACT.
Satiation Signals. Adiposity Signals. Central Integrating Circuits. Integration of Satiation and Adiposity Signals.
Journal Article. Central Control of Body Weight and Appetite. Woods , Stephen C. Woods, Department of Psychiatry, University of Cincinnati, East Galbraith Road, Cincinnati, Ohio Oxford Academic. David A. PDF Split View Views.
Cite Cite Stephen C. Select Format Select format. ris Mendeley, Papers, Zotero. enw EndNote. bibtex BibTex. txt Medlars, RefWorks Download citation. Permissions Icon Permissions. ABSTRACT Context. Open in new tab Download slide. TABLE 1. GI hormones that affect satiation. Effect on food intake. Open in new tab.
α-melanocyte-stimulating hormone;. Google Scholar PubMed. OpenURL Placeholder Text. Google Scholar Crossref. Search ADS. Google Scholar OpenURL Placeholder Text. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. Prolonged mild hyperglycemia induces vagally mediated compensatory increase in C-peptide secretion in humans.
Oxford, UK: Oxford University Press;. Relationships between gastric motility and gastric vagal afferent responses to CCK and GRP in rats differ. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin.
Food-related gastrointestinal signals activate caudal brainstem neurons expressing both NMDA and AMPA receptors. Cholecystokinin activates catecholaminergic neurons in the caudal medulla that innervate the paraventricular nucleus of the hypothalamus in rats.
Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. The cholecystokinin receptor antagonist L, increases food intake in the rat by attenuation of endogenous cholecystokinin. Potent cholecystokinin antagonist L, stimulates food intake in rats.
Rapid development of tolerance to the behavioural actions of cholecystokinin. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats.
Interaction between GLP-1 and CCK in inhibiting food intake and appetite in men. Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.
Gene structure of human cholecystokinin CCK type-A receptor: body fat content is related to CCK type-A receptor gene promoter polymorphism. Nutrient, neural and endocrine control of glucagon-like peptide secretion.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Glucagonlike peptide-1 GLP-1 participation in ileal brake induced by intraluminal peptones in rat. Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Dipeptidyl-peptidase IV CD26 —role in the inactivation of regulatory peptides. Effects of GLP 7—36 NH2, GLP 7—37 , and GLP 9—36 NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.
Role of central nervous system glucagon-like peptide-1 receptors in enteric glucosesensing. Glucagon-like peptide-1 GLP-1 receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
Central administration of GLP 7—36 amide inhibits food and water intake in rats. A role for glucagon-like peptide-1 in the central regulation of feeding {lsqb;see comments{rsqb;.
Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.
Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Central infusion of leptin and GLP-1 7—36 amide differentially stimulate c-Fos-like immunoreactivity in the rat brain.
Colocalization of glucagon-like peptide-1 GLP-1 receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness.
You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary Necessary. Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie Duration Description cookielawinfo-checkbox-analytics 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional 11 months The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary 11 months This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". It does not store any personal data.
Functional Functional. Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features. Performance Performance. Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics Analytics. Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. Advertisement Advertisement. Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns.
These cookies track visitors across websites and collect information to provide customized ads. Others Others. Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
This cookie is set by GDPR Cookie Consent plugin.
Appetite control system understanding ststem the Sports supplementation systems that regulate food intake Appettie body weight has increased immensely Appetite control system the past decade. Brain centres, including the Appwtite, brainstem Sports supplementation Appetiet centres, Appetite control system via Sports supplementation which regulate energy homeostasis. Insulin and Alpetite synthesized Herbal Cholesterol Management adipose tissue reflect the long-term nutritional status of the body and are able to influence these circuits. Circulating gut hormones modulate these pathways acutely and result in appetite stimulation or satiety effects. This review discusses central neuronal networks and peripheral signals which contribute energy homeostasis, and how a loss of the homeostatic process may result in obesity. It also considers future therapeutic targets for the treatment of obesity. In most adults, adiposity and body weight are remarkably constant despite huge variations in daily food intake and energy expended.
0 thoughts on “Appetite control system”